D.A. Davidson & CO. Raises Position in Moderna, Inc. (NASDAQ:MRNA)

D.A. Davidson & CO. lifted its stake in Moderna, Inc. (NASDAQ:MRNAFree Report) by 8.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,113 shares of the company’s stock after acquiring an additional 827 shares during the period. D.A. Davidson & CO.’s holdings in Moderna were worth $1,045,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Archer Investment Corp boosted its stake in Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after buying an additional 222 shares during the period. Spire Wealth Management boosted its stake in Moderna by 15.2% during the third quarter. Spire Wealth Management now owns 2,380 shares of the company’s stock valued at $246,000 after buying an additional 314 shares during the period. Banque Cantonale Vaudoise boosted its stake in Moderna by 8.5% during the third quarter. Banque Cantonale Vaudoise now owns 35,989 shares of the company’s stock valued at $3,717,000 after buying an additional 2,833 shares during the period. First Command Advisory Services Inc. bought a new stake in Moderna during the third quarter valued at $165,000. Finally, Amalgamated Bank boosted its stake in Moderna by 0.9% during the third quarter. Amalgamated Bank now owns 85,029 shares of the company’s stock valued at $8,783,000 after buying an additional 729 shares during the period. 64.51% of the stock is owned by institutional investors.

Moderna Trading Down 6.7 %

MRNA opened at $87.41 on Monday. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $177.37. The company has a current ratio of 2.46, a quick ratio of 2.35 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average price is $96.62 and its 200-day moving average price is $96.00.

Insider Activity at Moderna

In related news, insider Arpa Garay sold 564 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $78.34, for a total transaction of $44,183.76. Following the transaction, the insider now owns 3,690 shares in the company, valued at approximately $289,074.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the sale, the president now directly owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Arpa Garay sold 564 shares of Moderna stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $78.34, for a total value of $44,183.76. Following the sale, the insider now directly owns 3,690 shares in the company, valued at $289,074.60. The disclosure for this sale can be found here. Insiders have sold a total of 106,899 shares of company stock worth $10,732,838 in the last 90 days. Company insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several research analyst reports. The Goldman Sachs Group dropped their price objective on Moderna from $269.00 to $231.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. Canaccord Genuity Group began coverage on Moderna in a research report on Wednesday, November 29th. They set a “hold” rating and a $82.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price target on shares of Moderna in a research report on Friday, January 12th. JPMorgan Chase & Co. lowered their price target on Moderna from $93.00 to $90.00 and set a “neutral” rating on the stock in a research report on Friday, December 1st. Finally, HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and lowered their price target for the company from $89.00 to $69.00 in a research report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $123.96.

Get Our Latest Analysis on MRNA

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.